Register Login

CYTOKINETICS INC (CYTK)

(10% Negative) CYTOKINETICS INC (CYTK) Announces Delay in published Development Timeline Due to Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Aug. 28, 2026, 1:22 p.m.

    📋 CYTOKINETICS INC (CYTK) - Clinical Trial Update

    Filing Date: 2026-08-28

    Accepted: 2026-08-28 09:21:49

    Event Type: Clinical Trial Update

    Event Details:

    CYTOKINETICS INC (CYTK) Announces Clinical Trial Update CYTOKINETICS INC (CYTK) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: published, Results
    • Clinical Stage: clinical trial, Phase 3
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Regulatory Process
    • Collaboration: Congress

    🔬 Clinical Development Pipeline (CYTOKINETICS INC):

    Product Type Development Stage Therapeutic Area Source
    Placebo to match CK-4021586 Other Phase PHASE2 Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) ClinicalTrials.gov
    Aficamten Other Phase PHASE2 Pediatric ClinicalTrials.gov
    Omecamtiv Mecarbil (OM) Other Phase PHASE3 Heart Failure ClinicalTrials.gov
    CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) Other Phase PHASE2 Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) ClinicalTrials.gov
    Placebo Other Phase PHASE3 Heart Failure ClinicalTrials.gov
    Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg) Other Phase PHASE3 Obstructive Hypertrophic Cardiomyopathy (oHCM) ClinicalTrials.gov
    Placebo to match metoprolol succinate Other Phase PHASE3 Obstructive Hypertrophic Cardiomyopathy (oHCM) ClinicalTrials.gov
    Placebo to match aficamten Other Phase PHASE3 Obstructive Hypertrophic Cardiomyopathy (oHCM) ClinicalTrials.gov
    Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg) Other Phase PHASE3 Obstructive Hypertrophic Cardiomyopathy (oHCM) ClinicalTrials.gov
    CK-1827452 Other Phase PHASE2 Heart Failure ClinicalTrials.gov
    omecamtiv mecarbil Other Phase PHASE1 Heart Failure ClinicalTrials.gov
    Placebo capsule Other Phase PHASE2 Heart Failure ClinicalTrials.gov
    Placebo iv infusion Other Phase PHASE2 Heart Failure ClinicalTrials.gov
    CK-1827452 25mg capsule Other Phase PHASE2 Heart Failure ClinicalTrials.gov
    CK-1827452 48 mg and 11 mg iv infusion Other Phase PHASE2 Heart Failure ClinicalTrials.gov
    CK-1827452 12.5mg capsule Other Phase PHASE2 Heart Failure ClinicalTrials.gov
    CK-1827452 24mg and 6 mg iv infusion Other Phase PHASE2 Heart Failure ClinicalTrials.gov
    Riluzole 50 MG Other Phase PHASE2 Amyotrophic Lateral Sclerosis ClinicalTrials.gov
    CK-2017357 Other Phase PHASE2 Amyotrophic Lateral Sclerosis ClinicalTrials.gov
    Ispinesib Other Phase PHASE1 Breast Neoplasms ClinicalTrials.gov
    CK-2017357 (Part B) Other Phase PHASE2 Amyotrophic Lateral Sclerosis ClinicalTrials.gov
    Placebo (Part B) Other Phase PHASE2 Amyotrophic Lateral Sclerosis ClinicalTrials.gov
    Riluzole 50 MG (Part B) Other Phase PHASE2 Amyotrophic Lateral Sclerosis ClinicalTrials.gov
    CK-2017357 (Part A) Other Phase PHASE2 Amyotrophic Lateral Sclerosis ClinicalTrials.gov
    Placebo (Part A) Other Phase PHASE2 Amyotrophic Lateral Sclerosis ClinicalTrials.gov
    500 mg CK-2017357 Other Phase PHASE2 Amyotrophic Lateral Sclerosis ClinicalTrials.gov
    250 mg CK-2017357 Other Phase PHASE2 Amyotrophic Lateral Sclerosis ClinicalTrials.gov
    375 mg CK-2017357 Other Phase PHASE2 Intermittent Claudication ClinicalTrials.gov
    SB-743921 Other Phase PHASE1 Non-Hodgkin's Lymphoma ClinicalTrials.gov
    Riluzole Other Phase PHASE2 Amyotrophic Lateral Sclerosis ClinicalTrials.gov
    Placebo tablets Other Phase PHASE2 Amyotrophic Lateral Sclerosis ClinicalTrials.gov
    Tirasemtiv Other Phase PHASE3 Amyotrophic Lateral Sclerosis ClinicalTrials.gov
    50 mg Omecamtiv Mecarbil Other Phase PHASE2 Heart Failure With Reduced Ejection Fraction ClinicalTrials.gov
    37.5 mg Omecamtiv Mecarbil Other Phase PHASE2 Heart Failure With Reduced Ejection Fraction ClinicalTrials.gov
    25 mg Omecamtiv Mecarbil Other Phase PHASE2 Heart Failure With Reduced Ejection Fraction ClinicalTrials.gov
    AMG 423 Other Phase PHASE1 Heart Failure ClinicalTrials.gov
    Omecamtiv Mecarbil Swellable Core Technology F2 Other Phase PHASE2 Modified Release Oral Formulation ClinicalTrials.gov
    Omecamtiv Mecarbil Matrix F2 Formulation Other Phase PHASE2 Modified Release Oral Formulation ClinicalTrials.gov
    Omecamtiv Mecarbil Matrix F1 Formulation Other Phase PHASE2 Modified Release Oral Formulation ClinicalTrials.gov
    Standard of Care Other Phase PHASE3 Heart Failure ClinicalTrials.gov
    Moxifloxacin Other Phase PHASE1 Healthy Participants ClinicalTrials.gov
    Aficamten-matching Placebo Other Phase PHASE1 Healthy Participants ClinicalTrials.gov
    Reldesemtiv Other Phase PHASE3 Amyotrophic Lateral Sclerosis ClinicalTrials.gov
    Placebo for CK-3828136 Other Phase PHASE1 Healthy Participants ClinicalTrials.gov
    CK-3828136 Other Phase PHASE1 Healthy Participants ClinicalTrials.gov
    CK-3773274 Other Phase PHASE1 Obstructive Hypertrophic Cardiomyopathy ClinicalTrials.gov
    CK-3773274 - Tablets Other Phase PHASE1 Symptomatic Obstructive Hypertrophic Cardiomyopathy ClinicalTrials.gov
    Placebo - Granules in Capsule Other Phase PHASE1 Symptomatic Obstructive Hypertrophic Cardiomyopathy ClinicalTrials.gov
    CK-3773274 - Granules in Capsule Other Phase PHASE1 Symptomatic Obstructive Hypertrophic Cardiomyopathy ClinicalTrials.gov
    Placebo for CK-4021586 Other Phase PHASE1 Healthy Participants ClinicalTrials.gov
    CK-4021586 Other Phase PHASE1 Healthy Participants ClinicalTrials.gov
    Aficamten (5 - 20 mg) Other Phase PHASE2 Symptomatic Hypertrophic Cardiomyopathy (HCM) ClinicalTrials.gov
    Placebo for CK-3773274 Other Phase PHASE2 Hypertrophic Cardiomyopathy (HCM) ClinicalTrials.gov
    CK-3773274 (10 - 30 mg) Other Phase PHASE2 Hypertrophic Cardiomyopathy (HCM) ClinicalTrials.gov
    CK-3773274 (5 - 15 mg) Other Phase PHASE2 Hypertrophic Cardiomyopathy (HCM) ClinicalTrials.gov
    Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) Other Phase PHASE3 Obstructive Hypertrophic Cardiomyopathy (oHCM) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: CYTOKINETICS INC
    • Ticker Symbol: CYTK

Search

News categories